Iterum Therapeutics plc (ITRMF) Long-Term Deferred Tax (2017 - 2022)

Iterum Therapeutics has reported Long-Term Deferred Tax for 6 years, with the latest figure at $36.1 million in Q4 2022.

• On a quarterly basis, Long-Term Deferred Tax rose 8.55% year-over-year to $36.1 million in Q4 2022; TTM through Dec 2022 was $36.1 million, a 8.55% increase from a year earlier, with the FY2022 full-year figure at $36.1 million, up 8.55% from the prior year.
• Long-Term Deferred Tax was $36.1 million for Q4 2022 at Iterum Therapeutics, up from $33.2 million in the prior quarter.
• The five-year high for Long-Term Deferred Tax was $36.1 million in Q4 2022, with the low at $13.6 million in Q4 2018.
• Average Long-Term Deferred Tax over 5 years is $27.9 million, with a median of $30.3 million recorded in 2020.
• The sharpest annual moves came in 2018 and 2022: Long-Term Deferred Tax soared 152.32% in 2018, then climbed 8.55% in 2022.
• Over 5 years, Long-Term Deferred Tax stood at $13.6 million in 2018, then jumped by 91.93% to $26.2 million in 2019, then grew by 15.52% to $30.3 million in 2020, then advanced by 9.77% to $33.2 million in 2021, then rose by 8.55% to $36.1 million in 2022.
• The last three Long-Term Deferred Tax figures came in at $36.1 million (Q4 2022), $33.2 million (Q4 2021), and $30.3 million (Q4 2020), per Business Quant data.